BioCentury
ARTICLE | Translation in Brief

Bayer eyes Johns Hopkins

Bayer and Johns Hopkins partner for retinal diseases

June 25, 2015 7:00 AM UTC

Bayer AG (Xetra:BAYN) is extending its reach in ophthalmology research through a new collaboration with The Johns Hopkins University. The deal marks the third broad university collaboration for the company in the U.S. - all signed within the last five years - and hints the company is keen to catch up with its pharma competitors in tapping into academic research.

Bayer's five-year collaboration with the Wilmer Eye Institute at Johns Hopkins aims to develop therapeutics for diseases affecting the back of the eye. The partners are initially focusing on retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt's disease and retinal vein occlusion. ...